Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome
Translational Oncology · 2025-08 · 58 · 102431
DOI: 10.1016/j.tranon.2025.102431 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2025-08. Verfasst von Yating Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Sichuan Province, Innovative Research Group Project of the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Colitis-associated colorectal cancer (CAC), which stems from inflammatory bowel disease (IBD), exhibits a high mortality rate. Chronic inflammation can drive the development of colorectal cancer via diverse mechanisms; however, proteomic-level studies in this regard are currently scarce. The chemical drugs conventionally employed for treating IBD carry significant side effects, accentuating the exigency for novel therapeutic agents. We focused on carvacrol, a traditional Chinese medicine-derived monoterpene phenol with anti-inflammatory and antioxidant traits, though its role in colitis and CAC was unclear. Employing TMT-based proteomics, we identified the oxidative stress pathway as crucial in CAC, with ALB, ADAM10, and APCDD1 (hub genes) being vital. Using DSS and AOM/DSS mouse models, carvacrol significantly restored colonic length (p < 0.01) and re-established key tight junction proteins like ZO-1. It also downregulated mRNA levels of inflammatory mediators such as iNOS and IL-6. Moreover, 16S rRNA sequencing and fluorescence in situ hybridization (FISH) assays indicated that the potential mechanism might be ascribed to carvacrol's modulation of the abundance of specific microbiota, such as Lactobacillus, Escherichia coli/Shigella, and Lachnoclostridium. In subsequent investigations, we ascertained that carvacrol exerted remarkable efficacy in the AOM/DSS models, as it markedly reduced the number of colonic tumors (p < 0.05) and concurrently suppressed the disease activity index scores (p < 0.05). These results jointly suggest its prospective role in thwarting the progression of colitis-associated colorectal cancer. Collectively, our study substantiates that carvacrol efficiently safeguards the mucosal barrier and curbs tumorigenesis, potentially via the modulation of gut microbiota.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Huidong General Surgery Department of Zigong Fourth People's Hospita, Zigong, 643000, China.
- Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
- Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. Electronic address: yinyuan10@hotmail.com.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: denghongx@scu.edu.cn.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: dailei2016@scu.edu.cn.
Förderung
- Natural Science Foundation of Sichuan Province
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Sichuan University
- Key Research and Development Program of Sichuan Province
Zitieren
APA
Fan, Y., Chen, Y., Yang, H., Chen, N., Gu, X., Feng, X., Fang, C., Yin, Y., Deng, H., & Dai, L. (2025). Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome. Translational Oncology, 58, 102431. https://doi.org/10.1016/j.tranon.2025.102431
Vancouver
Fan Y, Chen Y, Yang H, Chen N, Gu X, Feng X, et al. Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome. Translational Oncology. 2025;58:102431. doi:10.1016/j.tranon.2025.102431
BibTeX
@article{Fan2025,
author = {Fan, Yating and Chen, Ye and Yang, Hua and Chen, Na and Gu, Xiangshuai and Feng, Xiaoliang and Fang, Chao and Yin, Yuan and Deng, Hongxin and Dai, Lei},
title = {Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome},
journal = {Translational Oncology},
year = {2025},
volume = {58},
pages = {102431},
doi = {10.1016/j.tranon.2025.102431}
}
EUVIMED